Axogen pays $200m for BioCircuit Technologies to bring sutureless nerve repair in-house
A $200m all-cash agreement to acquire BioCircuit Technologies puts Florida-based Axogen in position to absorb NerveTape, the first sutureless peripheral nerve repair device to earn FDA clearance, with closing expected in Q4 2026. The deal adds a hooks-based repair system to a portfolio that already includes the Avance nerve graft and the Axoguard range of nerve connectors and protectors.
Key takeaways
- Axogen agreed to acquire BioCircuit Technologies in a $200m all-cash deal, with closing expected in Q4 2026.
- The acquisition brings in NerveTape, the first sutureless peripheral nerve repair device to receive FDA clearance, which it obtained in July 2022.
- NerveTape uses miniature hooks to align and hold severed nerve ends together, enabling repair without the microsurgical precision that suture-based methods require.
- Axogen plans to use its direct sales force and existing hospital and surgeon relationships to speed NerveTape's market uptake beyond BioCircuit's independent reach.
- NerveTape faces new competition from Tissium's COAPTIUM CONNECT, which recently received FDA de novo authorization for peripheral nerve repair.
A $200m all-cash agreement to acquire BioCircuit Technologies puts Florida-based Axogen in position to absorb NerveTape, the first sutureless peripheral nerve repair device to earn FDA clearance, with closing expected in Q4 2026. The deal adds a hooks-based repair system to a portfolio that already includes the Avance nerve graft and the Axoguard range of nerve connectors and protectors.
NerveTape received FDA clearance in July 2022. The device uses miniature hooks to align and hold the ends of a severed nerve together, promoting healing without demanding the microsurgical precision that conventional suture-based repair requires. Axogen president and CEO Michael Dale said the technology "makes high-quality nerve repair simpler and more accessible for surgeons," and the company's argument is that lower technical barriers allow deployment across a broader range of surgeons and care settings than traditional approaches permit. CFO Lindsey Hartley described NerveTape as an "attractive growth asset" that she expects to contribute to revenue growth once the deal closes. Axogen also takes ownership of BioCircuit's technology platform, which the company says opens paths to further product development and potential expansion into new indications, though no specific programs were named.
The distribution case hinges on throughput. Axogen says its direct sales force and existing relationships with hospital contractors and surgeons are positioned to speed up NerveTape's market uptake and deepen penetration beyond what BioCircuit could reach independently. The device's reduced dependency on microsurgical skills is the operational lever: a broader pool of eligible surgeons expands the addressable order book across hospital settings.
Competition entering the sutureless segment
NerveTape's first-mover clearance is already under pressure. Tissium's COAPTIUM CONNECT recently received FDA de novo authorization for peripheral nerve repair and approaches the problem differently: a light-activated surgical gel joins severed nerve ends inside a bioresorbable, 3D-printed chamber. Its entirely atraumatic nature could give it a competitive edge over NerveTape's hook-based mechanism. Neuraptive Therapeutics also holds an exclusive license from Washington University in St. Louis for a bioresorbable peripheral nerve repair device, though that system still requires a surgical procedure.
The close date to watch is Q4 2026.
Filed by the newsroom of MarketPR on September 11, 2026. Source: finance.yahoo.com. Indicative figures are not investment advice.